Porphyria News and Research

RSS
AMT announces full year 2009 results; reports modest decrease in operating expenses

AMT announces full year 2009 results; reports modest decrease in operating expenses

Recent clinical trials in patients with ALBP show that SOMA 250 mg reduces disability

Recent clinical trials in patients with ALBP show that SOMA 250 mg reduces disability

AMT reaches another milestone in the official marketing authorisation process for Glybera

AMT reaches another milestone in the official marketing authorisation process for Glybera

AMT receives Innovation Credit to develop gene therapy treatment for DMD

AMT receives Innovation Credit to develop gene therapy treatment for DMD

Novartis presents 6-month results from its EVEREST study for PCV

Novartis presents 6-month results from its EVEREST study for PCV

Amsterdam Molecular Therapeutics provides third-quarter 2009 business updates

Amsterdam Molecular Therapeutics provides third-quarter 2009 business updates

Veterans Affairs establishes service-connection benefits for Vietnam Veterans

Veterans Affairs establishes service-connection benefits for Vietnam Veterans

Research to explore diagnosis and treatment of rare diseases

Research to explore diagnosis and treatment of rare diseases

Treatment for acute intermittent porphyria

Treatment for acute intermittent porphyria

Molecular missing link between fasting and acute attacks of porphyria

Molecular missing link between fasting and acute attacks of porphyria

Arsenic caused the madness of King George III

Arsenic caused the madness of King George III

Arsenic in King George III's hair contributed to bouts of madness

Arsenic in King George III's hair contributed to bouts of madness